Michl Johanna, Zimmer Jutta, Tarsounas Madalena
Genome Stability and Tumourigenesis Group, Department of Oncology, The CRUK-MRC Oxford Institute for Radiation Oncology University of Oxford, Oxford, UK.
Genome Stability and Tumourigenesis Group, Department of Oncology, The CRUK-MRC Oxford Institute for Radiation Oncology University of Oxford, Oxford, UK
EMBO J. 2016 May 2;35(9):909-23. doi: 10.15252/embj.201693860. Epub 2016 Apr 1.
The Fanconi anemia (FA) pathway plays a central role in the repair of DNA interstrand crosslinks (ICLs) and regulates cellular responses to replication stress. Homologous recombination (HR), the error-free pathway for double-strand break (DSB) repair, is required during physiological cell cycle progression for the repair of replication-associated DNA damage and protection of stalled replication forks. Substantial crosstalk between the two pathways has recently been unravelled, in that key HR proteins such as the RAD51 recombinase and the tumour suppressors BRCA1 and BRCA2 also play important roles in ICL repair. Consistent with this, rare patient mutations in these HR genes cause FA pathologies and have been assigned FA complementation groups. Here, we focus on the clinical and mechanistic implications of the connection between these two cancer susceptibility syndromes and on how these two molecular pathways of DNA replication and repair interact functionally to prevent genomic instability.
范可尼贫血(FA)通路在DNA链间交联(ICL)修复中起核心作用,并调节细胞对复制应激的反应。同源重组(HR)是双链断裂(DSB)修复的无差错途径,在生理细胞周期进程中,对于修复与复制相关的DNA损伤和保护停滞的复制叉是必需的。最近发现这两条通路之间存在大量相互作用,因为关键的HR蛋白,如RAD51重组酶以及肿瘤抑制因子BRCA1和BRCA2在ICL修复中也发挥重要作用。与此一致的是,这些HR基因中的罕见患者突变会导致FA病症,并已被归入FA互补组。在这里,我们重点关注这两种癌症易感性综合征之间联系的临床和机制意义,以及DNA复制和修复的这两条分子通路如何在功能上相互作用以防止基因组不稳定。